| 25 years of contrast-enhanced MRI: developments, current challenges and future perspectives J Lohrke, T Frenzel, J Endrikat, FC Alves, TM Grist, M Law, JM Lee, ... Advances in therapy 33, 1-28, 2016 | 392 | 2016 |
| A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg … J Endrikat, U Müller, B Düsterberg Contraception 55 (3), 131-137, 1997 | 135 | 1997 |
| Frequency of denial of pregnancy: results and epidemiological significance of a 1-year prospective study in Berlin J Wessel, J Endrikat, U Buscher Acta obstetricia et gynecologica Scandinavica 81 (11), 1021-1027, 2002 | 119 | 2002 |
| Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies J Endrikat, S Parke, D Trummer, W Schmidt, I Duijkers, C Klipping Contraception 78 (3), 218-225, 2008 | 110 | 2008 |
| A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia J Endrikat, H Shapiro, E Lukkari-Lax, M Kunz, W Schmidt, M Fortier Journal of Obstetrics and Gynaecology Canada 31 (4), 340-347, 2009 | 109 | 2009 |
| A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a … U Gaspard, J Endrikat, JP Desager, C Buicu, C Gerlinger, R Heithecker Contraception 69 (4), 271-278, 2004 | 108 | 2004 |
| A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism U Gaspard, A Scheen, J Endrikat, C Buicu, P Lefebvre, C Gerlinger, ... Contraception 67 (6), 423-429, 2003 | 97 | 2003 |
| A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg … J Endrikat, U Müller, B Düsterberg Contraception 55 (3), 131-137, 1997 | 90 | 1997 |
| A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol UH Winkler, AE Schindler, J Endrikat, B Düsterberg Contraception 53 (2), 75-84, 1996 | 81 | 1996 |
| An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and … J Endrikat, C Klipping, M Cronin, C Gerlinger, A Ruebig, W Schmidt, ... Contraception 65 (3), 215-221, 2002 | 74 | 2002 |
| Extended use combination comprising estrogens and progestins B Duesterberg, J Endrikat, R Schuermann US Patent App. 10/721,825, 2005 | 72 | 2005 |
| Elevated risk for neonatal outcome following denial of pregnancy: results of a one-year prospective study compared with control groups J Wessel, J Endrikat, U Büscher Walter de Gruyter 31 (1), 29-35, 2003 | 71 | 2003 |
| Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study J Endrikat, B Düsterberg, A Ruebig, C Gerlinger, T Strowitzki Contraception 60 (5), 269-274, 1999 | 71 | 1999 |
| A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg … SO Skouby, J Endrikat, B Düsterberg, W Schmidt, C Gerlinger, J Wessel, ... Contraception 71 (2), 111-117, 2005 | 69 | 2005 |
| Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen J Endrikat, B Düsterberg, P Reilhac US Patent 6,995,149, 2006 | 65 | 2006 |
| Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results C Gerlinger, L Bamber, F Leverkus, C Schwenke, C Haberland, ... BMC research notes 12 (1), 1-6, 2019 | 63 | 2019 |
| A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 μg or 30 μg ethinylestradiol in combination with … J Endrikat, E Mih, B Düsterberg, K Land, C Gerlinger, W Schmidt, ... Contraception 69 (3), 179-187, 2004 | 63 | 2004 |
| A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 μg or 30 μg ethinylestradiol in combination with … J Endrikat, E Mih, B Düsterberg, K Land, C Gerlinger, W Schmidt, ... Contraception 69 (3), 179-187, 2004 | 63 | 2004 |
| The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia J Endrikat, G Vilos, C Muysers, M Fortier, E Solomayer, E Lukkari-Lax Archives of gynecology and obstetrics 285, 117-121, 2012 | 56 | 2012 |
| Extended Use Combination Comprising Estrogens And Progestins B Düsterberg, J Endrikat, R Schurmann US Patent App. 10/584,045, 2008 | 56 | 2008 |
